Cardiac amyloidosis: An approach to diagnosis and management

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 7, 2010, Pages 1007-1013

  Halwani, Omaira ^a   Delgado, Diego H ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

cardiac amyloidosis; heart failure; heart transplantation; myocardial biopsy; noninvasive diagnosis

Indexed keywords

AMYLOID P COMPONENT; ANGIOTENSIN II ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; TROPONIN T; WARFARIN; ANTICOAGULANT AGENT;

CARDIOMYOPATHY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE MANAGEMENT; ELECTROCARDIOGRAPHY; HEART AMYLOIDOSIS; HEART FAILURE; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HEREDITARY SYSTEMIC AMYLOIDOSIS; HUMAN; PROGNOSIS; REVIEW; SENILE AMYLOIDOSIS; SYSTEMIC AMYLOID LIGHT CHAIN AMYLOIDOSIS; AMYLOIDOSIS; BIOPSY; CARDIOMYOPATHIES; CARDIOMYOPATHY, RESTRICTIVE; CLASSIFICATION; COMPLICATION; ENDOCARDIUM; HEART MUSCLE; PATHOLOGY;

AMYLOIDOSIS; ANTICOAGULANTS; BIOPSY; CARDIOMYOPATHIES; CARDIOMYOPATHY, RESTRICTIVE; DIAGNOSIS, DIFFERENTIAL; DIURETICS; ENDOCARDIUM; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; MYOCARDIUM; PROGNOSIS;

EID: 77954520434     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.41     Document Type: Review

References (28)

1. Selvanayagam J, Hawkins P, Paul B et al. Evaluation and management of the cardiac amyloidosis. J. Am. Coll. Cardiol. 50(2), 2101-2110 (2007).
2. McCarthy R, Kasper E. A review of the amyloidoses that infiltrate the heart. Clin. Cardiol. 21, 547-552 (1998).
3. Merlini G, Belloti V. Molecular mechanisms of amyloidosis. N. Engl. J. Med. 349, 583-596 (2003).
4. Merlini G, Westermark P. The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J. Intern. Med. 255, 159-178 (2004).
5. Falk R, Comenzo R, Skinner M. The systemic amyloidoses. N. Engl. J. Med. 337(13), 898-909 (1997).
6. Falk R. Diagnosis and management of the cardiac amyloidoses. Circulation 112, 2047-2060 (2005).
7. Kristen A, Schnabelb P, Wintera B et al. High prevalence of amyloid in 150 surgically removed heart valves - a comparison of histological and clinical data reveals a correlation to atheroinflammatory conditions. Cardiovasc. Pathol. DOI: 10.1016/j. carpath.2009.04.005 (2009) (Epub ahead of print).
8. Dubrey A, Anderson C, Chamarthi B et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. Q. J. Med. 91, 141-157 (1998).
9. Kristen A, Perz J, Schonland S et al. Non-invasive predictors of survival in cardiac amyloidosis. Eur. J. Heart Fail. 9, 617-624 (2007).
10. Murtagh B, Hammill SC, Gertz MA et al. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement Am. J. Cardiol. 95, 535-537 (2005).
11. Dubrey SW, Bilazarian S, LaValley M et al. Signal-averaged electrocardiography in patients with AL (primary) amyloidosis. Am. Heart J. 134(6), 994-1001 (1997).
12. Munshi L, Ross HJ, Chen C et al. Use of echocardiography in the diagnosis of cardiac AL amyloidosis. An analysis of presumed and endomyocardial biopsy-proven disease. Can. J. Cardiolog. 22D, 133 (2006).
13. Kristen A, Perz J, Schonland S et al. Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis. J. Heart Lung Transplant. 26, 1313-1319 (2007).
14. Maceira A, Joshi J, Prasad S et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111, 186-193 (2005). (Pubitemid 40139730)
15. Disperenzieri A, Kyle RA, Gertz MA et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 361, 1787-1789 (2003).
16. Palladini G, Lavatelli F, Russo P et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 107, 3854-3858 (2006).
17. Goodman J, Gilmore JD, Lachmann HJ et al. Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br. J. Haematol. 134, 417-425 (2006).
18. Lachmann HJ, Gallimore R, Gilmore JD et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br. J. Haematol. 122, 78-84 (2003).
19. Dubrey SW, Burke MM, Hawkins PN, Banner NR. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J. Heart Lung Transplant. 23, 1142-1153 (2004).
20. Sanchorawala V, Wright DG, Seldin DC et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: result of prospective randomized trial. Bone Marrow Transplant. 33, 381-388 (2004).
21. Bird J, Behrens J, Westin J; United Kingdom Myeloma Forum. Guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined. Br. J. Haematol. 125, 681-700 (2004)
22. Saba N, Sutton D, Ross H et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant. 101, 766-769 (1999).
23. Maurer M, Raina A, Hesdorffer C et al. Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure. Transplantation 83, 539-545 (2007).
24. Hall R, Hawkins P. Cardiac transplantation for AL amyloidosis. Br. Med. J. 309, 1135-1137 (1994).
25. Kpodonu J, Massad M, Caines A et al. Outcome of heart transplantation in patients with amyloid cardiomyopathy. J. Heart Lung Transplant. 24, 1763-1765 (2005). (Pubitemid 41641848)
26. Dubrey S, Burke M, Khaghani A et al. Long term results of heart transplantation in patients with amyloid heart disease. Heart 85, 202-207 (2001).
27. Trulock EP, Christie JD, Edwards LB et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report - 2007. J. Heart Lung Transplant. 26(8), 782-795 (2007).
28. Kristen A, Sack F, Schonland S et al. Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis. Eur. J. Heart Fail. 11, 1014-1020 (2009).